- $1.66bn
- $1.37bn
- $184.42m
Stoke Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Brief: Stoke Therapeutics Reports Q3 Financial Results And Provides Business Updates
Stoke Therapeutics Inc expected to post a loss of 68 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Starbucks, Keycorp, Vaxcyte
SVB starts Stoke Therapeutics with 'outperform'; shares rise
Brief: Stoke Therapeutics Enrolls First Patient In A Natural History Study Of People Living With Autosomal Dominant Optic Atrophy
Stoke Therapeutics rises on update for rare disease drug
Stoke Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Stoke Therapeutics reports Q2 results
Brief: Stoke Therapeutics Files For Mixed Shelf Of Up To $400 Million
Stoke Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Stoke Therapeutics Reports First Quarter Financial Results And Provides Business Updates
Brief: Stoke Therapeutics Inc - Cash Runway Anticipated To Fund Operations Into 2025
Stoke Therapeutics Inc expected to post earnings of 36 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP- Air Products and Chemicals, Armstrong World Industries, Lennar
Stoke Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Stoke Therapeutics Reports Fourth Quarter And Full Year 2021 Financial Results And Provides Business Updates
Stoke Therapeutics Inc expected to post a loss of 62 cents a share - Earnings Preview
Brief: Acadia Pharmaceuticals And Stoke Therapeutics Announce Collaboration To Pursue Multiple RNA-Based Treatments For Severe And Rare Genetic Neurodevelopmental Diseases